Loading...

HeraMED

ASX:HMD
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HMD
ASX
A$19M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

HeraMED Limited develops and sells pregnancy monitoring solutions for home and professional use in Australia, Europe, and Israel. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • HeraMED has significant price volatility in the past 3 months.
HMD Share Price and Events
7 Day Returns
4.5%
ASX:HMD
2.3%
AU Medical Equipment
1.8%
AU Market
1 Year Returns
-
ASX:HMD
-1.1%
AU Medical Equipment
6%
AU Market
HMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
HeraMED (HMD) 4.5% -9.8% 31.4% - - -
AU Medical Equipment 2.3% 4% -0.1% -1.1% 44.3% 109.3%
AU Market 1.8% 3.9% 7.8% 6% 20.5% 8.4%
1 Year Return vs Industry and Market
  • No trading data on HMD.
  • No trading data on HMD.
Price Volatility
Industry
5yr Volatility vs Market

HMD Value

 Is HeraMED undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for HeraMED. This is due to cash flow or dividend data being unavailable. The share price is A$0.23.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for HeraMED's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are HeraMED's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:HMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.10
ASX:HMD Share Price ** ASX (2019-04-26) in AUD A$0.23
ASX:HMD Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.701 $0.16
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of HeraMED.

ASX:HMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:HMD Share Price ÷ EPS (both in USD)

= 0.16 ÷ -0.10

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HeraMED is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • HeraMED is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does HeraMED's expected growth come at a high price?
Raw Data
ASX:HMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for HeraMED, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on HeraMED's assets?
Raw Data
ASX:HMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.05
ASX:HMD Share Price * ASX (2019-04-26) in AUD A$0.23
ASX:HMD Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.701 $0.16
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.77x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:HMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:HMD Share Price ÷ Book Value per Share (both in USD)

= 0.16 ÷ 0.05

3.25x

* Primary Listing of HeraMED.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HeraMED is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess HeraMED's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. HeraMED has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HMD Future Performance

 How is HeraMED expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HeraMED has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is HeraMED expected to grow at an attractive rate?
  • Unable to compare HeraMED's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare HeraMED's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare HeraMED's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:HMD Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:HMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:HMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -2 -4
2018-09-30 0 -1 -2
2018-06-30 0 0 -1
2018-03-31 0 0 -1
2017-12-31 -1 -1
2016-12-31 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if HeraMED is high growth as no earnings estimate data is available.
  • Unable to determine if HeraMED is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:HMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from HeraMED Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:HMD Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.10
2018-09-30 -0.03
2018-06-30
2018-03-31
2017-12-31 -0.02
2016-12-31 -21.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if HeraMED will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine HeraMED's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. HeraMED's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. HeraMED's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess HeraMED's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
HeraMED has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HMD Past Performance

  How has HeraMED performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare HeraMED's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • HeraMED does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare HeraMED's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare HeraMED's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
HeraMED's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from HeraMED Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:HMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.08 -3.77 2.14 0.47
2018-09-30 0.05 -2.35 1.28 0.44
2018-06-30 0.03 -0.92 0.43 0.41
2018-03-31 0.01 -0.86 0.42 0.33
2017-12-31 -0.79 0.40 0.24
2016-12-31 -2.12 0.41 1.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if HeraMED has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if HeraMED has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if HeraMED improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess HeraMED's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
HeraMED has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HMD Health

 How is HeraMED's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up HeraMED's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • HeraMED is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • HeraMED's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of HeraMED's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 27.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from HeraMED Company Filings, last reported 3 months ago.

ASX:HMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.34 0.16 4.04
2018-09-30 4.34 0.16 4.04
2018-06-30 1.57 0.00 0.22
2018-03-31 1.57 0.00 0.22
2017-12-31 0.21 0.30 0.05
2016-12-31 0.88 0.22 1.35
  • HeraMED's level of debt (3.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if HeraMED's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • HeraMED has sufficient cash runway for 2.1 years based on current free cash flow.
  • HeraMED has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -4% each year.
X
Financial health checks
We assess HeraMED's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. HeraMED has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HMD Dividends

 What is HeraMED's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from HeraMED dividends.
If you bought A$2,000 of HeraMED shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate HeraMED's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate HeraMED's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:HMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as HeraMED has not reported any payouts.
  • Unable to verify if HeraMED's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of HeraMED's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as HeraMED has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess HeraMED's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can HeraMED afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. HeraMED has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HMD Management

 What is the CEO of HeraMED's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Groberman
CEO Bio

Mr. David Groberman is a Co-Founder and Chief Executive Officer of HeraMED Limited and also has been its Director since September 25, 2018. Mr. Groberman has been developing multi-disciplinary medical devices for the last 15 years. He gained extensive knowledge and capabilities, leading some of the most challenging projects in this field, ranging from implants to invasive mechanical, electro-mechanical and opto-mechanical instruments, surgical apparatuses and applicators, monitoring, diagnosis and scanning equipment. He spent over 8 years as Co-Founder and CTO at Meytar R&D. Mr. Groberman holds a B.Sc. cum laude from the faculty of bio-mechanical engineering in TAU and he is an alumnus of the IDF elite computer science unit.

CEO Compensation
  • Insufficient data for David to compare compensation growth.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team

David Groberman

TITLE
Co-Founder

Tal Slonim

TITLE
Co-Founder

Sivan Sadan

TITLE
Chief Financial Officer
TENURE
0.8 yrs

Michael Nenner

TITLE

Henry Jordan

TITLE
Head of Investor Relations

Ariel Laden

TITLE
Head of UX

Josef Tovbin

TITLE
Chief Medical Officer

Stephen Buckley

TITLE
Company Secretary
Board of Directors Tenure

Average tenure of the HeraMED board of directors in years:

0.6
Average Tenure
  • The average tenure for the HeraMED board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ron Weinberger

TITLE
Non-Executive Chairman

David Groberman

TITLE
Co-Founder
TENURE
0.6 yrs

Tal Slonim

TITLE
Co-Founder
TENURE
0.6 yrs

Doron Birger

TITLE
Non-Executive Director
AGE
67
TENURE
0.5 yrs

David Hinton

TITLE
Non-Executive Director
AGE
55
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess HeraMED's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. HeraMED has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HMD News

Simply Wall St News

What Percentage Of HeraMED Limited (ASX:HMD) Shares Do Insiders Own?

HeraMED is a smaller company with a market capitalization of AU$18m, so it may still be flying under the radar of many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that. … institutional investors have bought into the company

Simply Wall St -

HMD Company Info

Description

HeraMED Limited develops and sells pregnancy monitoring solutions for home and professional use in Australia, Europe, and Israel. The company’s product is the HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus’ heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. HeraMED Limited was founded in 2011 and is based in West Perth, Australia.

Details
Name: HeraMED Limited
HMD
Exchange: ASX
Founded: 2011
A$19,256,345
87,528,841
Website: http://www.hera-med.com
Address: HeraMED Limited
46-50 Kings Park Road,
Level 2,
West Perth,
Western Australia, 6005,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX HMD Ordinary Share Australian Securities Exchange AU AUD 12. Dec 2018
Number of employees
Current staff
Staff numbers
0
HeraMED employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 10:36
End of day share price update: 2019/04/26 00:00
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.